BioLineRx Ltd. [NASDAQ: BLRX] loss -2.87% or -0.06 points to close at $2.03 with a heavy trading volume of 14060341 shares. The company report on September 11, 2023 at 7:00 AM that BioLineRx Announces FDA Approval of APHEXDA™ (motixafortide) in Combination with Filgrastim (G-CSF) to Mobilize Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Patients with Multiple Myeloma.
– APHEXDA is the first innovation in stem cell mobilization for multiple myeloma to be approved in the U.S. in a decade -.
Top 5 EV Tech Stocks to Buy for 2023
The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".
Click Here to Download the FREE Report.
Sponsored
– One dosage of APHEXDA plus filgrastim enabled a majority of patients to achieve the collection goal of ≥ 6 million hematopoietic stem cells among a contemporary population of multiple myeloma patients -.
It opened the trading session at $2.32, the shares rose to $2.33 and dropped to $2.01, the range by which the price of stock traded the whole day. The daily chart for BLRX points out that the company has recorded 256.70% gains over the past six months. However, it is still -269.09% lower than its most recent low trading price.
If we look at the average trading volume of 683.11K shares, BLRX reached to a volume of 14060341 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about BioLineRx Ltd. [BLRX]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for BLRX shares is $12.50 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on BLRX stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Maxim Group have made an estimate for BioLineRx Ltd. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on May 18, 2017.
The Average True Range (ATR) for BioLineRx Ltd. is set at 0.22 The Price to Book ratio for the last quarter was 5.97, with the Price to Cash per share for the same quarter was set at 0.50.
Trading performance analysis for BLRX stock
BioLineRx Ltd. [BLRX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 0.50. With this latest performance, BLRX shares gained by 34.44% in over the last four-week period, additionally plugging by 256.70% over the last 6 months – not to mention a rise of 21.56% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BLRX stock in for the last two-week period is set at 62.15, with the RSI for the last a single of trading hit 61.59, and the three-weeks RSI is set at 61.39 for BioLineRx Ltd. [BLRX]. The present Moving Average for the last 50 days of trading for this stock 1.60, while it was recorded at 2.23 for the last single week of trading, and 1.11 for the last 200 days.
BioLineRx Ltd. [BLRX]: A deeper dive into fundamental analysis
Return on Total Capital for BLRX is now -43.61, given the latest momentum, and Return on Invested Capital for the company is -38.70. Return on Equity for this stock declined to -42.85, with Return on Assets sitting at -32.07. When it comes to the capital structure of this company, BioLineRx Ltd. [BLRX] has a Total Debt to Total Equity ratio set at 24.24. Additionally, BLRX Total Debt to Total Capital is recorded at 19.51, with Total Debt to Total Assets ending up at 16.13. Long-Term Debt to Equity for the company is recorded at 20.37, with the Long-Term Debt to Total Capital now at 16.39.
Reflecting on the efficiency of the workforce at the company, BioLineRx Ltd. [BLRX] managed to generate an average of -$1,710,894 per employee.BioLineRx Ltd.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.80 and a Current Ratio set at 2.80.
An analysis of Institutional ownership at BioLineRx Ltd. [BLRX]
The top three institutional holders of BLRX stocks are: VANGUARD GROUP INC with ownership of 1.31 billion shares, which is approximately 8.2089%. BLACKROCK INC., holding 1.04 billion shares of the stock with an approximate value of $170.67 trillion in BLRX stocks shares; and BERKSHIRE HATHAWAY INC, currently with $150.98 trillion in BLRX stock with ownership which is approximately 5.7381%.
